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Abstract Accurate identification of breast cancer patients
most likely to benefit from adjuvant systemic therapies is
crucial. Better understanding of differences between
methods can lead to an improved ER, PgR, and HER-2
assessment. The purpose of this preplanned translational
research is to investigate the correlation of central IHC/
FISH assessments with microarray mRNA readouts of ER,
PgR, and HER-2 status in the MINDACT trial and to
determine if any discordance could be attributed to intra-
tumoral heterogeneity or the DCIS and normal tissue
components in the specimens. MINDACT is an interna-
tional, prospective, randomized, phase III trial investigat-
ing the clinical utility of MammaPrint in selecting patients
with early breast cancer for adjuvant chemotherapy
(n = 6694 patients). Gene-expression data were obtained
by TargetPrint; IHC and/or FISH were assessed centrally
(n = 5788; 86 %). Macroscopic and microscopic evalua-
tion of centrally submitted FFPE blocks identified 1427
cases for which the very same sample was submitted for
gene-expression analysis. TargetPrint ER had a positive
agreement of 98 %, and a negative agreement of 95 % with
central pathology. Corresponding figures for PgR were 85
and 94 % and for HER-2 72 and 99 %. Agreement of
mRNA versus central protein was not different when the
same or a different portion of the tumor tissue was ana-
lyzed or when DCIS and/or normal tissue was included in
the sample subjected to mRNA assays. This is the first
large analysis to assess the discordance rate between pro-
tein and mRNA analysis of breast cancer markers, and to
look into intratumoral heterogeneity, DCIS, or normal tis-
sue components as a potential cause of discordance. The
observed difference between mRNA and protein assess-
ment for PgR and HER-2 needs further research; the pre-
sent analysis does not support intratumoral heterogeneity
or the DCIS and normal tissue components being likely
causes of the discordance.
Keywords Breast cancer  ER  PgR  HER2 
Concordance  Tumor heterogeneity  Hormone receptor 
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Introduction
Accurate identification of breast cancer patients most likely
to benefit from adjuvant systemic therapies is crucial.
Estrogen receptor (ER) and progesterone receptor (PgR)
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content in the primary tumor of patients with early-stage
invasive breast cancer are powerful predictors of response
to adjuvant endocrine therapies. It is recommended that
endocrine receptors be measured in all primary breast
cancer specimens, and endocrine expression is the primary
basis for selection of adjuvant systemic therapy [1, 2].
HER-2 positivity in breast cancer is a prognostic factor of
tumor aggressiveness and a predictive factor for response
to anti HER-2 treatment. Early and accurate HER-2 testing
of all breast cancer patients at primary diagnosis is essen-
tial for optimal disease management [3].
ASCO/CAP recommendations for optimal ER, PgR, and
HER-2 assessments describe the laboratory testing
requirements for testing, and serve as the golden standard
for current early breast cancer patient diagnostics [3, 4].
Other methods for assessing ER, PgR, and HER-2 such
as mRNA microarray and RT-PCR expression have been
commercially available for quite some time and are being
acknowledged as potential reliable future diagnostic
adjuncts depending on clinical utility studies [3–5].
Several large studies are available comparing mRNA
versus pathology and generally reporting overall good
concordance; these studies, however, do not address the
likely causes of the discordances encountered [6, 7].
Better understanding of differences between methods
can lead to an improved ER, PgR, and HER-2 assessment.
mRNA-based assays could potentially serve as an adjunct
tool for ER, PgR, and HER-2 assessment.
A previous analysis of a subset of the MINDACT
population (n = 619) indicated that local pathology results
for ER, PgR, and HER-2 were in overall good to high
concordance with central pathology, confirming the high
quality of stratification in MINDACT [8]. The current pre-
planned analysis of the complete MINDACT dataset allows
for the unique opportunity of looking into the concordance
rate and the possible causes of any discordance between
mRNA-based and IHC/FISH assessments of hormone
receptors and HER2.
MINDACT is an international, prospective, randomized,
phase III trial investigating the clinical utility of Mam-
maPrint versus standard clinicopathological criteria (Ad-
juvant!Online) to select patients with early breast cancer
for adjuvant chemotherapy. Central assessment of the main
standard histopathological features of the tumors were
performed as well as mRNA expression analysis of ER,
PgR, and HER-2, providing a unique opportunity to look at
concordance and discordance between these methodologies
and look into potential causes of any discordances found.
The aim of this pre-planned translational research was to
evaluate the agreement of central IHC/FISH assessments
versus microarray mRNA readouts by TargetPrint (com-
mercially available microarray-based test) of ER, PgR, and
HER-2, and to assess whether any differences between
mRNA and central pathology could be due to intratumoral
heterogeneity or by the DCIS and/or normal tissue com-
ponents in the samples undergone mRNA assays.
Methods
Patients
Female patients (N = 6694) with histologically proven
operable invasive breast cancer and 0–3 positive lymph
nodes were enrolled in MINDACT between February 2007
and July 2011 [9, 10]. Clinical Trials number:
NCT00433589. The protocol was approved by independent
ethics committees and medical authorities. All patients
provided written informed consent. The study was con-
ducted in accordance with the Declaration of Helsinki and
good clinical practice guidelines.
Tumor samples
Prior to enrollment for randomization and stratification, local
pathology assessment of hormone receptor andHER-2 status
was determined, and a frozen core biopsy (3–6 mm) of the
surgical tumor sample was sent to Agendia NV (Amsterdam,
TheNetherlands) forMammaPrint and TargetPrint analyses.
For translational research, a representative diagnostic
paraffin tissue block of each tumor was sent from each par-
ticipating center to the European Institute of Oncology
(EIO), (Milan, Italy) for central pathology re-assessment
(Fig. 1). TargetPrint readout was available for all 6694
patients. Central pathology results were unavailable for 867
patients because the sample had not been submitted for
central assessment. Among the 5788 patients with central
pathology results, 39 had incomplete data (1 for ER, 7 for
PgR, 32 for HER-2) and 12 equivocal HER-2 IHC and FISH
(Fig. 2).
ER, PgR, and HER-2 assessment
Gene-expression data and central laboratory assessments
were assessed as described previously [8].
mRNA and IHC/FISH discordancy analysis
To investigate tumor heterogeneity, we assessed whether
the same tumor sample submitted to the the central
pathology laboratory was also used for the gene-expression
analysis. When a core biopsy punch hole was found in the
blocks submitted for central pathology, it was assumed that
the very same samples underwent central assessment and
TargetPrint assay. In absence of such a hole, the assess-
ments were assumed not to have been performed on the
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same block, but on a different part of the tumor. The 6694
FFPE (H&E) slides were assessed for presence or absence
of a core biopsy punch hole in the tumor sample (Fig. 3).
Additional retrospective investigations were carried out
to investigate whether any differences between mRNA
assays and central pathology for ER and HER-2 could be
explained by the DCIS and/or normal tissue components in
the biopsy sample submitted for TargetPrint analysis. To this
purpose, 141 blinded scanned H&E sections of the frozen
samples submitted for TargetPrint analyses were reviewed
by the central pathology laboratory, and the extent of DCIS
and normal tissue was semi-quantitatively assessed as a
percent of the whole section area. These cases were selected
as follows: 31 ER-negative cases by central pathology
assessment and ER-positive by TargetPrint analysis; 30
randomly selected control samples ER-negative both by
central IHC and TargetPrint analysis; 50 HER-2-negative
cases by central IHC/FISH and HER-2-positive by Tar-
getPrint analysis; and30 randomly selected control samples
HER-2-negative both by central IHC/FISH and TargetPrint.
The selection was performed by the trial statistician with no
interference from the pathologist and molecular biologists.
Fig. 1 Sample schedule for
translational preplanned
analysis, with the 2 comparative
analyses indicated: A The
agreement of central IHC/FISH
assessments versus microarray
mRNA readouts by
TargetPrint of ER, PgR, and
HER-2 and B Sub-study to
assess whether the differences
between mRNA and central
pathology could be caused by
tumor heterogeneity
Fig. 2 Data overview and
sample availability
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Statistical analysis
Only the independent statistician of the EORTC had simulta-
neous access to both clinical and genomic data and performed
the correlation analysis. Statistical calculationswere conducted
using SAS 9.2 (SAS Institute Inc., Cary, USA). This pre-
planned translational research investigated 2 comparisons A
and B, depicted in Fig. 1. Analysis (A) investigated the
agreement of central IHC/FISH assessments versusmicroarray
mRNAreadouts byTargetPrint. The statistics includedpositive
and negative agreement [11]; positive (PPV) and negative
(NPV) predictive value; percentage of concordance; and
Cohen’s j coefficient [12]. And secondly (B), using Fisher’s
exact test for association, we investigated whether the differ-
ences between mRNA and central pathology could be caused
by tumor heterogeneity or by the occurrence of DCIS and/or
normal tissue.
Results
Correlation central pathology and TargetPrint
for ER, PgR, and HER-2 (A)
Figures 4A through4Cshow thecentral pathologyassessments
for ER, PgR, and HER-2 as integer percentages and for HER-2
as five categories. The TargetPrint results are mRNA expres-
sion scores on a continuous scale. For ER and PgR, most dis-
cordances were seen in the lower ranges of expression.
Comparison of central assessment with TargetPrint
(Table 1) indicated a highly similar overall performance,
with a concordance of 97 % (j = 0.87) for ER, 96 % for
HER-2 (j = 0.76), and a slightly lower concordance for
PgR (87 %; j = 0.65).
For ER, the positive agreement was 98 % and the neg-
ative agreement was 95 % with a PPV of 99.4 and an NPV
of 83.4. The positive agreement for PgR was 85 % and the
negative agreement was 94 %. PPV was 98.3 and the NPV
59.7. For HER2, the positive agreement for TargetPrint
was 72 %, with a PPV of 84.3, and an NPVof 97.2.
Also provided in Table 2 are the agreement statistics for
ER and PgR by central pathology using 10 % invasive
tumor cells as cut-off instead of 1 % compared with
Fig. 3 H&E-stained section with a core biopsy punch hole caused by
the MammaPrint biopsy device provided in the sample kit
Fig. 4 A–C Comparative depiction of mRNA score on a continuous
scale for TargetPrint versus central pathology assessment as integer
percentage for ER (A), PgR (B), and as five categories for HER-2 (C).
Random trimmed noise was added to the data points to increase
visibility
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TargetPrint. For both receptors, the agreement increases
significantly when using the 10 % cut-off for the IHC
results, reaching a concordance of 98 % (j = 0.91) for ER
and of 90 % for PgR (j = 0.76).
Analyses of discordant mRNA and IHC/FISH
results (B)
Table 2 shows how the agreement statistics for samples
with a hole versus samples without such a hole are very
similar for all measures of agreement.
Fisher’s exact test shows that the extent of DCIS and
normal tissue in the sample analyzed for TargetPrint
analysis is not associated with the discordant result for ER
(Table 3). For HER-2 however, the test shows a greater
extent of DCIS and/or normal cells for TargetPrint HER-2-
negative and IHC/FISH HER-2-negative compared to
TargetPrint HER-2-positive and IHC/FISH HER-2-nega-
tive (Table 4). However, given that the sample size is
rather small this could be a chance finding.
Discussion
The current study confirms the previously reported high
level of concordance between microarray TargetPrint
readout and central pathology analyses for ER, with lower
negative agreement for PgR and lower positive agreement
for HER-2. These results confirm that mRNA assessment
of ER by TargetPrint may be a reliable adjunct to IHC
assessment [8].The lower agreement for PgR has been
reported by several others [7, 13, 14]. Whether mRNA PgR
assessment is indeed more strongly associated with clinical
outcome compared with IHC PgR assessment as suggested
is a hypothesis to be tested when MINDACT outcome data
will become available [15]. The positive agreement for
HER-2 mRNA analysis in the current series is only 72 %,
and in line with previously reported figures for mRNA
analysis [16, 17].
The agreement for ER and PgR between central
pathology and TargetPrint results increases significantly
using 10 % invasive tumor cells as an IHC cut-off instead
of 1 %, reaching a concordance rate of 98 % (j = 0.91)
for ER and of 90 % for PgR (j = 0.76). This may be
explained by the TargetPrint originally having been trained
on the 10 % cut-off, although none of the training samples
had a score between 1 and 10 % [5]. Whether this
improvement in concordance will also lead to improved
endocrine responsiveness will need to be tested, since there
are also indications for these samples having basal-like
features implying reduced endocrine responsiveness and
increased sensitivity to chemotherapy [18].
The likely causes of the discordant results between
mRNA readout and pathology assessment of ER, PgR, and
HER-2 have not been elucidated thus far. Suggested
Table 1 Agreement of central pathology versus mRNA Agreement statistics of central pathology assessment versus TargetPrint, including 2
IHC cut-offs for ER and PgR (1 and 10 %)
Concordance
(95 % CI)






ER (1 %) 97.3 % (96.9–97.7) 0.874 (0.855–0.894) 97.6 (5002/5127) 95.3 (629/660) 99.4 (5002/5033) 83.4 (629/754) 5787
ER (10 %) 98.1 % (97.7–98.4) 0.913 (0.897–0.929) 98.6 (4993/5065) 94.5 (682/722) 99.2 (4993/5033) 90.5 (682/754) 5787
PgR (1 %) 86.9 % (86.0–87.7) 0.649 (0.626–0.671) 85.3 (3998/4689) 93.8 (1024/1092) 98.3 (3998/4066) 59.7 (1024/1715) 5781
PgR (10 %) 90.4 % (89.7–91.2) 0.761 (0.743–0.780) 90.8 (3908/4303) 89.3 (1320/1478) 96.1 (3908/4066) 77.0 (1320/1715) 5781
HER-2 96.1 % (95.6–96.6) 0.757 (0.726–0.788) 72.3 (391/541) 98.6 (5142/5215) 84.3 (391/464) 97.2 (5142/5292) 5756
Table 2 Tumor heterogeneity analysis of central pathology versus mRNA
Concordance
(95 % CI)






ER Hole 97.0 % (96.1–97.9) 0.864 (0.825–0.904) 97.4 (1217/1250) 94.1 (160/170) 99.2 (1217/1227) 82.9 (160/193) 1420
ER No hole 97.5 % (97.0–97.9) 0.880 (0.858–0.903) 97.7 (3673/3761) 95.8 (459/479) 99.5 (3673/3693) 83.9 (459/547) 4240
PgR Hole 87.8 % (86.0–89.4) 0.666 (0.621–0.710) 86.5 (996/1151) 92.9 (250/269) 98.1 (996/1015) 61.7 (250/405) 1420
PgR No hole 86.8 % (85.7–87.8) 0.647 (0.621–0.673) 85.1 (2919/3432) 94.0 (754/802) 98.4 (2919/2967) 59.5 (754/1267) 4234
HER-2 Hole 95.8 % (94.8–96.9) 0.764 (0.706–0.822) 73.6 (109/148) 98.4 (1245/1265) 84.5 (109/129) 97.0 (1245/1284) 1413
HER-2 No hole 96.2 % (95.6–96.8) 0.756 (0.720–0.792) 71.8 (280/390) 98.7 (3775/3826) 84.6 (280/331) 97.2 (3775/3885) 4216
Agreement statistics for central pathology assessments versus TargetPrint, for central samples with a biopsy hole and thus assumed to have no
tumor heterogeneity in the sample sent for mRNA analysis, and samples without such a hole and thus assumed to be heterogeneous from the
mRNA sample
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possible causes such as intratumoral heterogeneity, DCIS,
and/or normal tissue components have not yet been ana-
lyzed in a randomized patient cohort. The MINDACT trial
is a prospectively designed study to determine the clinical
utility of MammaPrint in selecting patients with early
breast cancer for adjuvant chemotherapy and enrolled 6694
patients. The extensive sample availability per patient in
the central pathology laboratory, together with whole
genome mRNA expression analysis provides for a unique
comparative dataset able to address these issues: Could
tumor heterogeneity or the DCIS and normal tissue com-
ponents be responsible for the discordant results when
different areas of the tumor are analyzed by IHC and
mRNA assays? Because the same level of agreement for
mRNA versus central pathology protein assessment was
obtained when the very same tissue samples or different
blocks were analyzed by the 2 methods, it is concluded that
tumor heterogeneity cannot justify the reported discordant
results. Similarly, the observed differences between mRNA
and protein assessment for hormone receptors and HER-2
cannot be justified by the extent of DCIS and normal tissue.
In conclusion, in this large randomized multicenter pan-
European trial setting with central pathology and mRNA
assessments available for 86 % of patients, TargetPrint
mRNA assessment shows high concordance with central
assessment of ER, but lower concordance rates for PgR and
HER-2. This means that mRNA assessment of ER by
TargetPrint can be a reliable adjunct to IHC assessment,
but for PgR and HER-2 the stand of care remains IHC
assessment.
The current analysis indicates that tumor heterogeneity
and extent of DCIS and normal tissue components are not
the likely causes of any differences between mRNA and
protein assessment. This insight may ultimately lead to
further research to determine what biological differences
are being detected by the two methods.
Since MINDACT outcome data are expected in 2016,
the clinical implications for differences between the two
assessments for PgR and HER-2 can be tested.
Acknowledgments We are grateful to all women participating in
this study, all the investigators, surgeons, pathologists, and research
nurses, the National Coordinating Centers/BIG Groups (BOOG,
CaCTUS, CEEOG, FNCLCC, GOIRC, IBCSG, SAKK, SOLTI,
WSG), and World Courier. This trial has funding grants from the
European Commission Framework Programme VI (FP6-LSHC-CT-
2004-503426), the Breast Cancer Research Foundation, Novartis, F.
Hoffman La Roche, Sanofi-Aventis, the National Cancer Institute
(NCI), the EBCC-Breast Cancer Working Group (BCWG grant for
the MINDACT biobank), the Jacqueline Seroussi Memorial Foun-
dation (2006 JSMF award), Prix Mois du Cancer du Sein (2004
award), Susan G. Komen for the Cure (SG05-0922-02), Fondation
Belge Contre le Cancer (SCIE 2005-27), Dutch Cancer Society
(KWF), Association Le Cancer du Sein, Parlons-en!, Deutsche
Krebshilfe, and the Grant Simpson Trust and Cancer Research UK.
This trial was supported by the EORTC Charitable Trust. Whole
genome analysis was provided in kind by Agendia.





Total n = 61 Fisher exact test
p value
% DCIS or normal cells
0 19 (63 %) 15 (48 %) 34 (56 %) 0.30
1–30 7 (23 %) 13 (42 %) 20 (33 %)
31–60 2 (7 %) 3 (10 %) 5 (8 %)
[60 1 (3 %) 0 (0 %) 1 (2 %)
No slide found 1 (3 %) 0 (0 %) 1 (2 %)
Fisher’s exact test for the association of DCIS and/or normal tissue components and ER discordant rates, comparing 30 cases both negative by
TargetPrint and central assessment with 31 cases positive by TargetPrint and negative at central assessment





Total n = 80 Fisher exact
test p value
% DCIS or normal cells
0 17 (57 %) 40 (80 %) 57 (71 %) 0.0067
1–30 11 (37 %) 10 (20 %) 21 (26 %)
31–60 1 (3 %) 0 (0 %) 1 (1 %)
[60 0 (0 %) 0 (0 %) 0 (0 %)
Fisher’s exact test for the association of DCIS and/or normal tissue components and HER-2 discordant rate, comparing 30 cases both negative by
TargetPrint and central assessment with 50 cases positive by TargetPrint and negative at central assessment
468 Breast Cancer Res Treat (2016) 155:463–469
123
Compliance with ethical standards
Conflict of Interest FS and LSS were employees for Agendia at the
time of analysis. AG is an employee of Agendia. LV is a founder of
Agendia and has stock ownership. All remaining authors have
declared no competing interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. National Comprehensive Cancer Network: NCCN Clinical
Practice Guidelines in Oncology. Breast Cancer. Version 3.2010
2. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S
et al (2007) American Society of Clinical Oncology 2007 update
of recommendations for the use of tumor markers in breast
cancer. J Clin Oncol 2007(25):5287–5312
3. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM,
Allison KH et al (2013) Recommendations for human epidermal
growth factor receptor 2 testing in breast cancer: American
Society of Clinical Oncology/College of American Pathologists
clinical practice guideline update. J Clin Oncol 31(31):3997–4013
4. Hammond ME, Hayes DF, Dowsett M et al (2010) American
Society of Clinical Oncology/College of American Pathologists
guideline recommendations for immunohistochemical testing of
estrogen and progesterone receptors in breast cancer. J Clin
Oncol 28:2784–2795
5. Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mes-
quita JM, Bender R et al (2009)Microarray-based determination of
estrogen receptor, progesterone receptor, andHER2 receptor status
in breast cancer. Clin Cancer Res 15(22):7003–7011
6. Perez EA, Baehner FL, Butler SM, Thompson EA, Dueck AC,
Jamshidian F et al (2015) The relationship between quantitative
human epidermal growth factor receptor 2 gene expression by the
21-gene reverse transcriptase polymerase chain reaction assay
and adjuvant trastuzumab benefit in Alliance N9831. Breast
Cancer Res 17(1):133
7. Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu
M-L et al (2008) Estrogen- and progesterone-receptor status in
ECOG 2197: comparison of immunohistochemistry by local and
central laboratories and quantitative reverse transcription
polymerase chain reaction by central laboratory. J Clin Oncol
26(15):2473–2481
8. Viale G, Bogaerts J, Slaets L, Rutgers E, van’t Veer L, Piccart-
Gebhart MJ et al (2014) High concordance of protein (by IHC),
gene (by FISH; HER2 only) and microarray readout (by Tar-
getPrint) of ER/PR/HER2: results from the MINDACT trial. Ann
Oncol 25(4):816–823
9. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van’t
Veer L, Rubio IT et al (2011) The EORTC 10041/BIG 03-04
MINDACT trial is feasible: results of the pilot phase. Eur J
Cancer 00:2742–2749
10. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Van ‘t
Veer LJ, Rubio IT et al. Baseline results of the EORTC
10041/MINDACT TRIAL (Microarray In Node 0-3 positive
Disease may Avoid ChemoTherapy). ECCO 2013
11. US Food and Drug Administration. Guidance for industry and
FDA staff: Statistical guidance on reporting results from studies
evaluating diagnostic tests. http://medical.cms.itri.org.tw/pdf/
u14.pdf Accessed 13 May 2015
12. Cohen J (1960) A coefficient of agreement for nominal scales.
Educ Psychol Meas 20:37–46
13. Ma XJ, Hilsenbeck SG, Wang W, Ding L, Sgroi DC, Bender RA
et al (2006) The HOXB13:IL17BR expression index is a prog-
nostic factor in early-stage breast cancer. J Clin Oncol
24:4611–4619
14. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R (2012) Semi-
quantitative immunohistochemical assay versus oncotype DX()
qRT-PCR assay for estrogen and progesterone receptors: an
independent quality assurance study. Mod Pathol 25(6):869–876
15. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T
et al (2010) A comparison of PAM50 intrinsic subtyping with
immunohistochemistry and clinical prognostic factors in tamox-
ifen-treated estrogen receptor-positive breast cancer. Clin Cancer
Res 16:5222–5232
16. Dabbs DJ, Klein ME, Mohsin SK, Tubbs RR, Shuai Y, Bhargava
R (2011) High false-negative rate of HER2 quantitative reverse
transcription polymerase chain reaction of the Oncotype DX test:
an independent quality assurance study. J Clin Oncol
29:4279–4285
17. Baehner FL, Achacoso N, Maddala T, Shak S, Quesenberry CP
Jr, Goldstein LC et al (2010) Human epidermal growth factor
receptor 2 assessment in a case-control study: comparison of
fluorescence in situ hybridization and quantitative reverse tran-
scription polymerase chain reaction performed by central labo-
ratories. J Clin Oncol 28:4300–4306
18. Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ
et al (2012) Estrogen receptor (ER) mRNA and ER-related gene
expression in breast cancers that are 1% to 10% ER-positive by
immunohistochemistry. J Clin Oncol 30(7):729–734
Breast Cancer Res Treat (2016) 155:463–469 469
123
